Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
<h4>Background</h4>Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.<h4>Patients and methods...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Public Library of Science (PLoS)
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/e996f890d27d40b4b39cabb6efbcd2ad |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:e996f890d27d40b4b39cabb6efbcd2ad |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:e996f890d27d40b4b39cabb6efbcd2ad2021-12-02T20:05:23ZEpidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.1932-620310.1371/journal.pone.0251761https://doaj.org/article/e996f890d27d40b4b39cabb6efbcd2ad2021-01-01T00:00:00Zhttps://doi.org/10.1371/journal.pone.0251761https://doaj.org/toc/1932-6203<h4>Background</h4>Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.<h4>Patients and methods</h4>This was an observational multicenter study that enrolled patients with lung cancer and thoracic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demographic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed.<h4>Results</h4>With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or ≥ 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty percent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overall survival was 9.5 months (95% CI 8.8-10.2 months), with an estimated rate of 70.3% (95% CI 67.2-73.4%), 38.9% (95% CI 35.4-42.4%), and 14.8% (95% CI 11.8-17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mortality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1-2. Long-term survival (> 2 years) was confirmed in 6.6% of patients, showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis.<h4>Conclusion</h4>This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients.Fernando FrancoEnric CarcerenyMaria GuiradoAna L OrtegaRafael López-CastroDelvys Rodríguez-AbreuRosario García-CampeloEdel Del BarcoOscar JuanFrancisco AparisiJose L González-LarribaManuel DomineJose M TrigoManuel CoboSara CerezoJulia CalzasBartomeu MassutíJoaquim Bosch-BarreraPaola García CovesMarta DomènechMariano ProvencioPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 16, Iss 6, p e0251761 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Fernando Franco Enric Carcereny Maria Guirado Ana L Ortega Rafael López-Castro Delvys Rodríguez-Abreu Rosario García-Campelo Edel Del Barco Oscar Juan Francisco Aparisi Jose L González-Larriba Manuel Domine Jose M Trigo Manuel Cobo Sara Cerezo Julia Calzas Bartomeu Massutí Joaquim Bosch-Barrera Paola García Coves Marta Domènech Mariano Provencio Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. |
| description |
<h4>Background</h4>Small-cell lung cancer (SCLC) is an aggressive disease with high metastatic potential and poor prognosis. Due to its low prevalence, epidemiological and clinical information of SCLC patients retrieved from lung cancer registries is scarce.<h4>Patients and methods</h4>This was an observational multicenter study that enrolled patients with lung cancer and thoracic tumors, recruited from August 2016 to January 2020 at 50 Spanish hospitals. Demographic and clinical data, treatment patterns and survival of SCLC patients included in the Thoracic Tumor Registry (TTR) were analyzed.<h4>Results</h4>With a total of 956 cases, the age of 64.7 ± 9.1 years, 78.6% were men, 60.6% smokers, and ECOG PS 0, 1 or ≥ 2 in 23.1%, 53.0% and 23.8% of cases, respectively. Twenty percent of patients had brain metastases at the diagnosis. First-line chemotherapy (CT), mainly carboplatin or cisplatin plus etoposide was administered to >90% of patients. In total, 36.0% and 13.8% of patients received a second and third line of CT, respectively. Median overall survival was 9.5 months (95% CI 8.8-10.2 months), with an estimated rate of 70.3% (95% CI 67.2-73.4%), 38.9% (95% CI 35.4-42.4%), and 14.8% (95% CI 11.8-17.8%) at 6, 12 and 24 months respectively. Median progression-free survival was 6.3 months. Higher mortality and progression rates were significantly associated with male sex, older age, smoking habit, and ECOG PS 1-2. Long-term survival (> 2 years) was confirmed in 6.6% of patients, showing a positive correlation with better ECOG PS, poor smoking and absence of certain metastases at diagnosis.<h4>Conclusion</h4>This study provides an updated overview of the clinical situation and treatment landscape of ES-SCLC in Spain. Our results might assist oncologists to improve current clinical practice towards a better prognosis for these patients. |
| format |
article |
| author |
Fernando Franco Enric Carcereny Maria Guirado Ana L Ortega Rafael López-Castro Delvys Rodríguez-Abreu Rosario García-Campelo Edel Del Barco Oscar Juan Francisco Aparisi Jose L González-Larriba Manuel Domine Jose M Trigo Manuel Cobo Sara Cerezo Julia Calzas Bartomeu Massutí Joaquim Bosch-Barrera Paola García Coves Marta Domènech Mariano Provencio |
| author_facet |
Fernando Franco Enric Carcereny Maria Guirado Ana L Ortega Rafael López-Castro Delvys Rodríguez-Abreu Rosario García-Campelo Edel Del Barco Oscar Juan Francisco Aparisi Jose L González-Larriba Manuel Domine Jose M Trigo Manuel Cobo Sara Cerezo Julia Calzas Bartomeu Massutí Joaquim Bosch-Barrera Paola García Coves Marta Domènech Mariano Provencio |
| author_sort |
Fernando Franco |
| title |
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. |
| title_short |
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. |
| title_full |
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. |
| title_fullStr |
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. |
| title_full_unstemmed |
Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry. |
| title_sort |
epidemiology, treatment, and survival in small cell lung cancer in spain: data from the thoracic tumor registry. |
| publisher |
Public Library of Science (PLoS) |
| publishDate |
2021 |
| url |
https://doaj.org/article/e996f890d27d40b4b39cabb6efbcd2ad |
| work_keys_str_mv |
AT fernandofranco epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT enriccarcereny epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT mariaguirado epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT analortega epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT rafaellopezcastro epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT delvysrodriguezabreu epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT rosariogarciacampelo epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT edeldelbarco epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT oscarjuan epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT franciscoaparisi epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT joselgonzalezlarriba epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT manueldomine epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT josemtrigo epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT manuelcobo epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT saracerezo epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT juliacalzas epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT bartomeumassuti epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT joaquimboschbarrera epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT paolagarciacoves epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT martadomenech epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry AT marianoprovencio epidemiologytreatmentandsurvivalinsmallcelllungcancerinspaindatafromthethoracictumorregistry |
| _version_ |
1718375516023554048 |